Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 9, 2024.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:                                                                                             

Vivian Wu of Nektar Therapeutics

(628) 895-0661

For Media:

David Rosen of Argot Partners

(212) 600-1902

david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-2024-on-thursday-may-9-2024-after-close-of-us-based-financial-markets-302135009.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar announce its financial results for the first quarter of 2024?

Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024.

Who will host the conference call to review the financial results?

Howard Robin, President and CEO of Nektar Therapeutics, will host the conference call to review the financial results.

How can I access the press release and live webcast of the conference call?

The press release and live audio-only webcast of the conference call can be accessed through a link on the Home Page and Investors section of the Nektar website.

Until when will the webcast of the conference call be available for replay?

The web broadcast of the conference call will be available for replay through June 9, 2024.

How can I pre-register to access the conference call?

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN for access.